Cargando…
P53-independent partial restoration of the p53 pathway in tumors with mutated p53 through ATF4 transcriptional modulation by ERK1/2 and CDK9
A long-term goal in the cancer-field has been to develop strategies for treating p53-mutated tumors. A novel small-molecule, PG3-Oc, restores p53 pathway-signaling in tumor cells with mutant-p53, independently of p53/p73. PG3-Oc partially upregulates the p53-transcriptome (13.7% of public p53 target...
Autores principales: | Tian, Xiaobing, Ahsan, Nagib, Lulla, Amriti, Lev, Avital, Abbosh, Philip, Dicker, David T., Zhang, Shengliang, El-Deiry, Wafik S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890376/ https://www.ncbi.nlm.nih.gov/pubmed/33582407 http://dx.doi.org/10.1016/j.neo.2021.01.004 |
Ejemplares similares
-
A subset of CB002 xanthine analogs bypass p53-signaling to restore a p53 transcriptome and target an S-phase cell cycle checkpoint in tumors with mutated-p53
por: Hernandez Borrero, Liz, et al.
Publicado: (2021) -
The role of p53 in anti-tumor immunity and response to immunotherapy
por: Carlsen, Lindsey, et al.
Publicado: (2023) -
Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer
por: Zhang, Shengliang, et al.
Publicado: (2022) -
Small-Molecule NSC59984 Induces Mutant p53 Degradation through a ROS-ERK2-MDM2 Axis in Cancer Cells
por: Zhang, Shengliang, et al.
Publicado: (2022) -
Targeting Mutated p53: Naivete and Enthusiasm to Attempt the Impossible
por: El-Deiry, Wafik S.
Publicado: (2023)